'We need to do more': Mer­ck CEO Rob Davis high­lights M&A, deals strat­e­gy ahead of '28 Keytru­da patent cliff

With megablock­buster Keytru­da’s patent cliff loom­ing in 2028, Mer­ck has made some bold M&A moves in an at­tempt to find its next big mon­ey­mak­er, in­clud­ing last year’s $11.5 bil­lion ac­qui­si­tion of Ac­celeron. Ac­cord­ing to CEO Robert Davis, there’s plen­ty more of that com­ing in 2022.

The chief ex­ec­u­tive high­light­ed the Ac­celeron deal — in which the phar­ma gi­ant snapped up the po­ten­tial block­buster pul­monary ar­te­r­i­al hy­per­ten­sion (PAH) drug so­tater­cept — and last year’s Pan­dion Ther­a­peu­tics ac­qui­si­tion as ex­am­ples of the com­pa­ny’s ap­proach go­ing in­to the new year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.